Epi proColon Publications

More Information

You are here: epigenomics Websites > epiprocolon > E-Support Library > Epi proColon Publications

Epi proColon® Publications

Year Citation
2020 Peterse et al. (Journal of the National Cancer Institute) Comparing the cost-effectiveness of innovative colorectal cancer screening tests.
2019 D’Andrea et al. (Cancer Medicine) Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
2019 Roth et al. (American Health and Drug Benefits) Clinical and budget impact of increasing colorectal cancer screening by blood- and stool-based testing.
2019 Hitchins et al. (Open Gastro) Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. doi:10.1136/bmjgast-2019-000299
2019 Potter et al. (CAP Today) FDA-approved DNA blood test for colorectal cancer prompts patient to undergo colonoscopy
2018 Tierling et al. (Genetics and Epigenomics) Comprehensive Evaluation of Commercial Bisulfite-Based DNA Methylation Kits and Development of an Alternative Protocol With Improved Conversion Performance. doi:t0.1177/1179237X18766097
2018 Bhangu et al. (Annals of Surgery) Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. doi:10.1097/SLA.0000000000002901
2018 LeMieux (Clinical Omics) Eyeing Epigenetic Markers Identifying the Methylation Patterns of cfDNA Aids in Identifying Cancer’s Origin.
2018 Cai et al. (Journal of Clinical Epigenetics) Epi proColon®: Use of a Non-Invasive SEPT9 Gene Methylation Blood Test for Colorectal Cancer Screening: A National Laboratory Experience. doi: 10.21767/2472-1158.100092
2017 de Vos et al. (Journal of Clinical Epigenetics) Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA. doi: 10.21767/2472-1158.100040
2017 Song L. and Li Y. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years. Biomark. Med (doi:10.2217/bmm-2017-0091)
2017 Song L et. Al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep. 2017 Jun 8;7(1):3032. doi: 10.1038/s41598-017-03321-8.
2017 deVos T, Molnar B. Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA. J Clin Epigenet. 2017, 3:1. doi: 10.21767/2472-1158.100040
2017 Song, L. et al. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. J Cancer Res Clin Oncol (2017) 143: 1093. doi:10.1007/s00432-017-2363-0
2017 Inadomi J. Screening for Colorectal Neoplasia. N Engl J Med 2017; 376:149-156
2016 Nian J. et. al. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis Clin Transl Gastroenterol. 2017 Jan 19;8(1):e216. doi: 10.1038/ctg.2016.66
2016 Liles E. et. al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. http://dx.doi.org/10.1016/j.ctarc.2016.12.004
2016 Toth K. et. al. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients Pathol Oncol Res. 2016 Dec 30. doi: 10.1007/s12253-016-0174-2
2014 Johnson D et. al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLOS ONE. 9(6):1-8. e98238
2014 Potter N et. al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clinical Chemistry. 60(9):1183-1191
2014 deVos T et al. Blood-based tests for colorectal cancer screening. Clin Lab Int. Oct. 2014:18-20
2014 Pratt V. Are we ready for a blood-based test to detect colon cancer? (editorial). Clinical Chemistry. 60(9):1141-1142
2013 Laudabaum U et. al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated Septin9 DNA vs. current strategies. Cancer Epidemiology, Biomarkers & Prevention. Jun 24. PMID:23796793
2013 Heichman K. Blood-based testing for colorectal cancer screening. Molecular Diagnosis and Therapy. DOI 10.1007/s40291-013-0074-z
2013 Church T et. al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 63:317-325. Doi10.1136/gutjnl-2012-304149
2012 Lofton-Day C et. al. Opportunities and limitations of blood-based CRC screening tests. Practical Gastroenterology. 36(7):29-34
2011 Warren J et. al. Septin9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Medicine. 9:133
2010 Payne S et. al. From discovery to the clinic: the novel DNA methylation biomarker mSEPT9 for the detection of colorectal cancer in blood. Epigenomics. 2(4):575–585
2009 deVos T et. al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 55(7):1337-1346
2008 Lofton-Day C et. al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clinical Chemistry. (54)2:414-423